Table 1.
Susceptibility profile of Gram-negative rods recovered from urine samples
| Tested antibiotics | GNR | Enterobacterales | Group I EB | Group II EB | Group III EB | NF-GNR | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nb | Result | Nb | Result | Nb | Result | Nb | Result | Nb | Result | Nb | Result | |
| ESBL-PE | 2,092 | 106 (5.1%) | 2,092 | 106 (5.1%) | 1,572 | 75 (4.8%) | 374 | 30 (8%) | 146 | 1 (0.7%) | 29 | 0 (0%) |
| Penicillins | ||||||||||||
| Ampicillin | 2,100 | 608 (29%) | 2,092 | 608 (29.1%) | 1,572 | 608 (38.7%) | 374 | 0 (0%) | 146 | 0 (0%) | – | – |
| Amoxicillin/clavulanic acid | 2,099 | 1,566 (74.6%) | 2,092 | 1,565 (74.8%) | 1,572 | 1,240 (78.9%) | 374 | 325 (86.9%) | 146 | 0 (0%) | – | – |
| Piperacillin | 2,124 | 732 (34.5%) | 2,092 | 706 (33.7%) | 1,572 | 610 (38.8%) | 374 | 0 (0%) | 146 | 96 (65.8%) | 29 | 26 (89.7%) |
| Ticarcillin | 2,125 | 752 (35.4%) | 2,092 | 725 (34.7%) | 1,572 | 629 (40%) | 374 | 0 (0%) | 146 | 96 (65.8%) | 29 | 27 (93.1%) |
| Piperacillin/tazobactam | 2,124 | 2,012 (94.7%) | 2,091 | 1,982 (94.8%) | 1,571 | 1,502 (95.6%) | 374 | 344 (92%) | 146 | 136 (93.2%) | 29 | 28 (96.6%) |
| Temocillin | 1,318 | 1,286 (97.6%) | 1,317 | 1,286 (97.6%) | 1,044 | 1,030 (98.7%) | 193 | 186 (96.4%) | 80 | 70 (87.5%) | – | – |
| Mécillinam | 1,055 | 970 (91.9%) | 1,055 | 970 (91.9%) | 1,004 | 933 (92.9%) | 44 | 34 (77.3%) | 7 | 3 (42.9%) | – | – |
| Aztreonam | 687 | 622 (90.5%) | 669 | 611 (91.3%) | 625 | 585 (93.6%) | 37 | 21 (56.8%) | 7 | 5 (71.4%) | 16 | 11 (68.8%) |
| Cephalosporins | ||||||||||||
| Cefotaxime | 2,096 | 1,971 (94%) | 2,092 | 1,968 (94.1%) | 1,572 | 1,495 (95.1%) | 374 | 344 (92%) | 146 | 129 (88.4%) | – | – |
| Ceftazidime | 2,126 | 2,011 (94.6%) | 2,092 | 1,982 (94.7%) | 1,572 | 1,507 (95.9%) | 374 | 344 (92%) | 146 | 131 (89.7%) | 29 | 26 (89.7%) |
| Cefepime | 2,126 | 2,017 (94.9%) | 2,092 | 1,984 (94.8%) | 1,572 | 1,507 (95.9%) | 374 | 346 (92.5%) | 146 | 131 (89.7%) | 29 | 29 (100%) |
| Carbapenems | ||||||||||||
| Imipenem | 2,124 | 2,118 (99.7%) | 2,091 | 2,086 (99.8%) | 1,572 | 1,571 (99.9%) | 374 | 374 (100%) | 145 | 141 (97.2%) | 29 | 29 (100%) |
| Meropenem | 121 | 120 (99.2%) | 90 | 90 (100%) | 48 | 48 (100%) | 35 | 35 (100%) | 7 | 7 (100%) | 29 | 29 (100%) |
| Ertapenem | 2,080 | 2,076 (99.8%) | 2,078 | 2,074 (99.8%) | 1,567 | 1,567 (100%) | 368 | 367 (99.7%) | 143 | 140 (97.9%) | – | – |
| Aminoglycosides | ||||||||||||
| Amikacin | 2,120 | 2,084 (98.3%) | 2,089 | 2,054 (98.3%) | 1,570 | 1,546 (98.5%) | 373 | 364 (97.6%) | 146 | 144 (98.6%) | 29 | 28 (96.6%) |
| Tobramycin | 1,185 | 1,080 (91.1%) | 1,154 | 1,049 (90.9%) | 879 | 805 (91.6%) | 203 | 183 (90.1%) | 72 | 61 (84.7%) | 29 | 29 (100%) |
| Gentamycin | 2,111 | 1,960 (92.8%) | 2,080 | 1,929 (92.7%) | 1,564 | 1,453 (92.9%) | 373 | 351 (94.1%) | 143 | 125 (87.4%) | 29 | 29 (100%) |
| Fluoroquinolones | ||||||||||||
| Ofloxacin | 2,097 | 1,710 (81.5%) | 2,092 | 1,707 (81.6%) | 1,572 | 1,256 (79.9%) | 374 | 328 (87.7%) | 146 | 123 (84.2%) | – | – |
| Ciprofloxacin | 1,977 | 1,797 (90.9%) | 1,943 | 1,766 (90.9%) | 1,449 | 1,311 (90.5%) | 362 | 331 (91.4%) | 132 | 124 (93.9%) | 29 | 28 (96.6%) |
| Others | ||||||||||||
| TMP/SMX | 2,097 | 1,402 (66.9%) | 2,082 | 1,387 (66.6%) | 1,567 | 955 (60.9%) | 372 | 317 (85.2%) | 143 | 115 (80.4%) | 13 | 13 (100%) |
| Nitrofurantoin | 2,084 | 1,786 (85.7%) | 2,083 | 1,785 (85.7%) | 1,565 | 1,475 (94.2%) | 373 | 238 (63.8%) | 145 | 72 (49.7%) | – | – |
| Fosfomycin | 765 | 750 (98%) | 764 | 749 (98%) | 714 | 708 (99.2%) | 43 | 35 (81.4%) | 7 | 6 (85.7%) | – | – |
EB = Enterobacteriaceae; ESBL = extended-spectrum β-lactamases; GNR = Gram-negative rods; Nb = number of tested isolates; NF-GNR = nonfermentative GNR; PE = producing enterobacterales; TMP/SMX = trimethoprim/sulfamethoxazole.